Walmart shares slipped 1.2% in pre-open trading after Oppenheimer downgraded the retailer to Perform from Outperform and simultaneously removed its $140 price target. The broker said its decision reflects specific revenue risks stemming from pharmacy operations inside Walmart U.S.
Oppenheimer singled out the Inflation Reduction Act as a source of meaningful top-line pressure for Walmart’s pharmacy business, saying it expects that pressure to weigh on comparable-sales figures in the second quarter and potentially beyond. The firm also pointed to the stock’s premium valuation as leaving limited upside from current levels and noted that consensus Street forecasts appear to run ahead of longer-term guidance provided by company management.
Describing the outlook as a "less compelling outperformance case" for the shares in the near term, Oppenheimer issued the downgrade a little over two weeks before Walmart is scheduled to report second-quarter results on August 20. The timing of the analyst action adds to pre-earnings uncertainty for the retailer.
The downgrade intensified a difficult period for the stock. Walmart has pulled back significantly from its 52-week high of $135.16 amid broader worries about consumer spending and the lingering effects of inflation. Company commentary has underscored those concerns: Walmart CFO John David Rainey previously warned that shoppers could feel more financial strain in the second quarter as the tailwind from elevated tax refunds dissipates.
Market moves on the day underscored that the weakness in Walmart was largely company-specific. The broader U.S. market was moving in the opposite direction, with the S&P 500 gaining 0.4%, the Dow rising 1.3%, and the Nasdaq up 1.1% in intraday trading. Against that constructive market backdrop, the combination of a high-profile analyst rating cut, pre-earnings uncertainty, and pharmacy-driven revenue concerns left Walmart shares trading at $109.37, making the stock a notable laggard heading into the regular session.
Investors will be watching the upcoming Q2 report on August 20 for detail on comparable-sales trends and any additional color management provides on pharmacy performance and longer-term guidance. For now, the confluence of valuation concerns, analyst skepticism and specific regulatory impacts on pharmacy revenue is weighing on the stock.